Plus Therapeutics (NASDAQ:PSTV) Releases Quarterly Earnings Results, Misses Estimates By $0.43 EPS

Plus Therapeutics (NASDAQ:PSTV) released its quarterly earnings results on Friday. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.43), FiscalAI reports. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.The firm had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $1.11 million.

Plus Therapeutics Stock Performance

NASDAQ:PSTV remained flat at $3.70 during mid-day trading on Friday. The company’s stock had a trading volume of 62,111 shares, compared to its average volume of 116,506. The company has a 50 day moving average of $4.12 and a two-hundred day moving average of $5.44. The company has a market cap of $25.47 million, a price-to-earnings ratio of -1.61 and a beta of 1.40. Plus Therapeutics has a twelve month low of $2.90 and a twelve month high of $23.42.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in Plus Therapeutics in the 2nd quarter worth approximately $41,000. Susquehanna International Group LLP purchased a new position in Plus Therapeutics during the third quarter valued at approximately $46,000. Scientech Research LLC bought a new position in shares of Plus Therapeutics in the third quarter worth approximately $100,000. XTX Topco Ltd purchased a new stake in shares of Plus Therapeutics in the fourth quarter worth $127,000. Finally, State Street Corp increased its stake in shares of Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after purchasing an additional 127,000 shares in the last quarter. 3.28% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PSTV has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Friday, July 17th. Ascendiant Capital Markets dropped their target price on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Plus Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $56.40.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.